师资队伍

Andrew Lee 现任北京大学深圳研究生院化学生物与生物技术学院副教授，并在深圳湾实验室肿瘤研究所担任联合职务。他本科就读于耶鲁大学，并在斯坦福大学获得医学博士和博士学位。随后，Andrew在斯坦福医院的临床病理科接受医学住院医师培训，在此期间他专注于细胞/基因治疗的研究，并实现了细胞/基因治疗的首次临床试验。他在细胞/基因治疗的深入研究并推动其进入新的临床应用方面已发表60多篇论文。

Andrew Lee在细胞/基因治疗研究领域的成果发表在《Nature Medicine》、《Nature Biotechnology》、《Nature Biomedical Engineering》、《Cell》、《JAMA》和《Circulation》等期刊上。根据谷歌学术统计，他被引用超过9,000次，H指数为40。并且，Andrew Lee 的研究具有良好的应用前景，得到美国心脏协会、霍华德·休斯医学研究所以及全球前10大制药公司的支持。

1.) Chiang CL, Ma Y, Hou YC, Pan J, Chen SY, Chien MH, Zhang ZX, Hsu WH, Wang X, Zhang J, Li H, Sun L, Fallen S, Lee I, Chen XY, Chu YS, Zhang X, Cheng TS, Jiang W, Kim BYS, Reategui E, Lee R, Yuan Y, Liu HC, Wang K, Hsiao M, Huang CYF^#, Shan YS^#,Lee AS^#, Lee LJ^#. Dual targeted extracellular vesicles regulate oncogenic genes in advances pancreatic cancer.Nature Communications 2023;14(1):6692.^#=co-corresponding author. Impact Factor = 17.69

2) You Y, Tian Y, Yang Z, Shi J, Kwak KJ, Estania AP, Tong Y, Cao J, Chiang CL, Hsu WH, Liu Y, Shrank B, Huntoon K, lee D, Li Z, Zhao Y, Zhang H, Gallup T, Ha J, Dong S, Lu WJ, Bahrani E, Lee LJ, Teng L, Jiang W, Lan F^#, Kim BYS^#,Lee AS^#. Intradermally delivered mRNA-encapsulating extracellular vesicles for collagen-replacement therapy.Nature Biomedical Engineering2023;1-13.^#=corresponding author. Impact Factor = 29.23

3) Zhao L*,Lee AS*,Sasagawa K*, Sokol J, Wang Y, Ransom RC, Zhao X, Ma C, Steininger HM, Koepke LS, Borrelli MR, Brewer RE, Lee LLY, Huang X, Ambrosi TH, Sinha R, Hoover MY, Seita J, Weissman IL, Wu JC, Wan DC, Xiao J, Longaker MT, Nguyen PK, Chan CKF. Combination of distinct vascular stem / progenitor cells for neovascularization and ischemic rescue.Arteriosclerosis, Thrombosis, and Vascular Biology 2023:https://doi.org/10.1161/ATVBAHA.122.317943. *=equal contribution. Impact Factor = 10.51

4) Li X, Lu WJ, Li Y, Wu F, Bai R, Na S, Dong T, Zhang H,Lee AS^#, Wang Y^#, Lan F^#. MLP-deficient human pluripotent stem cell derived cardiomyocytes develop hypertrophic cardiomyopathy and heart failure phenotypes due to abnormal calcium handling.Cell Death and Disease2019;8(13):1-15.^#=co-corresponding author. Impact Factor = 12.07

5) Lee AS*, Inayathullah M*, Lijkwan M*, Zhao X, Sun W, Park S, Hong WX, Parekh M, Malkovskiy, Lau E, Qin X, Pothineni V, Sanchez-Freire V, Zhang W, Kooreman N, Ebert A, Chan C, Nguyen PK, Rajadas J, Wu JC. A novel slow release collagen matrix cross-linked with pro-survival factor analogs promotes stem cell survival for treatment of ischemic cardiovascular disease.Nature Biomedical Engineering2018;2(2):104-113. *=equal contribution

Impact Factor = 29.23